Published in Cancer Weekly, July 29th, 1996 Empty 22-nm subviral
particles purified from the plasma of chronic carriers were the
first HBV vaccines to be used in humans. The second, and current
generation of HBV vaccines consists of similar subviral
particles which have been produced as recombinant proteins in
stably transfected eukaryotic cell lines. In spite of their high
efficacy, the current subunit HBV vaccines are not widely used
in developing countries owing to the high... Want to see the
full article? Welcome to NewsRx! Learn more about a six-week,
no-risk free trial of Cancer Weekly NewsRx also is available at
LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters,
NewsEdge, and Dow Jones.